Regeneron Pharmaceuticals (REGN) Prepaid Assets (2009 - 2026)
Regeneron Pharmaceuticals (REGN) posted quarterly Prepaid Assets of $801.7 million for Q2 2026, up 39.6% year-over-year from $574.3 million in Q2 2025, and up 29.12% quarter-over-quarter from $620.9 million in Q1 2026.
Regeneron Pharmaceuticals (REGN) Prepaid Assets (2009 - 2026) Analysis & Trends
Regeneron Pharmaceuticals' Prepaid Assets history runs 18 years deep, the most recent figure standing at $801.7 million for Q2 2026.
- In Q2 2026, Prepaid Assets rose 39.6% year-over-year to $801.7 million; the TTM figure through Jun 2026 stood at $801.7 million (up 39.6% YoY), while the FY2025 annual figure was $474.8 million, up 35.97% from the prior year.
- Prepaid Assets for Q2 2026 stood at $801.7 million, up from $620.9 million in the prior quarter.
- The five-year high for Prepaid Assets was $801.7 million in Q2 2026, with the low at $349.2 million in Q4 2024.
- The 5-year median for Prepaid Assets is $457.6 million (2022), against an average of $499.7 million.
- The sharpest annual moves came in 2022 and 2023: Prepaid Assets surged 98.92% in 2022, then plunged 37.23% in 2023.
- Regeneron Pharmaceuticals' Prepaid Assets stood at $411.2 million in 2022, then retreated by 5.98% to $386.6 million in 2023, then decreased by 9.67% to $349.2 million in 2024, then jumped by 35.97% to $474.8 million in 2025, then soared by 68.85% to $801.7 million in 2026.
- Business Quant data shows REGN's Prepaid Assets at $801.7 million in Q2 2026, $620.9 million in Q1 2026, and $474.8 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 801.70 Mn |
| Mar 31, 2026 | 620.90 Mn |
| Dec 31, 2025 | 474.80 Mn |
| Sep 30, 2025 | 595.60 Mn |
| Jun 30, 2025 | 574.30 Mn |
| Mar 31, 2025 | 468.90 Mn |
| Dec 31, 2024 | 349.20 Mn |
| Sep 30, 2024 | 412.00 Mn |
| Jun 30, 2024 | 681.90 Mn |
| Mar 31, 2024 | 414.90 Mn |
| Dec 31, 2023 | 386.60 Mn |
| Sep 30, 2023 | 574.70 Mn |
| Jun 30, 2023 | 366.30 Mn |
| Mar 31, 2023 | 406.20 Mn |
| Dec 31, 2022 | 411.20 Mn |
| Sep 30, 2022 | 446.40 Mn |
| Jun 30, 2022 | 583.60 Mn |
| Mar 31, 2022 | 424.90 Mn |
| Dec 31, 2021 | 332.40 Mn |
| Sep 30, 2021 | 482.00 Mn |